Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to $1.1 million.

  • Maxcyte's Depreciation & Amortization (CF) rose 56.29% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year decrease of 80.28%. This contributed to the annual value of $4.3 million for FY2024, which is 345.24% up from last year.
  • As of Q3 2025, Maxcyte's Depreciation & Amortization (CF) stood at $1.1 million, which was up 56.29% from $1.1 million recorded in Q2 2025.
  • Maxcyte's 5-year Depreciation & Amortization (CF) high stood at $1.1 million for Q1 2024, and its period low was $315900.0 during Q1 2021.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $1.0 million (2023), whereas its average is $835536.8.
  • In the last 5 years, Maxcyte's Depreciation & Amortization (CF) soared by 12081.63% in 2022 and then plummeted by 408.35% in 2024.
  • Over the past 5 years, Maxcyte's Depreciation & Amortization (CF) (Quarter) stood at $416500.0 in 2021, then skyrocketed by 120.82% to $919700.0 in 2022, then increased by 19.82% to $1.1 million in 2023, then fell by 4.08% to $1.1 million in 2024, then grew by 1.42% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $1.1 million for Q2 2025, and $1.1 million during Q1 2025.